Literature DB >> 33929558

Early morbidity and dose-volume effects in definitive radiochemotherapy for locally advanced cervical cancer: a prospective cohort study covering modern treatment techniques.

Yvette Seppenwoolde1,2,3, Katarina Majercakova1,2,4, Martin Buschmann1,2, Elke Dörr1,2, Alina E Sturdza1, Maximilian P Schmid1, Richard Pötter1,2, Dietmar Georg5,6.   

Abstract

PURPOSE: Predicting morbidity for patients with locally advanced cervix cancer after external beam radiotherapy (EBRT) based on dose-volume parameters remains an unresolved issue in definitive radiochemotherapy. The aim of this prospective study was to correlate patient characteristics and dose-volume parameters to various early morbidity endpoints for different EBRT techniques, including volumetric modulated arc therapy (VMAT) and adaptive radiotherapy (ART). METHODS AND MATERIALS: The study population consisted of 48 patients diagnosed with locally advanced cervix cancer, treated with definitive radiochemotherapy including image-guided adaptive brachytherapy (IGABT). Multiple questionnaires (CTCAE 4.03, QLQ-C30 and EORTC QLQ-CX24) were assessed prospectively for patients treated with different EBRT techniques, including online adaptive VMAT. Contouring and treatment planning was based on the EMBRACE protocols. Acute toxicity, classified as general, gastrointestinal (GI) or genitourinary (GU) and their corresponding dose-volume histograms (DVHs) were first correlated by applying least absolute shrinkage and selection operator (LASSO) and subsequently evaluated by multiple logistic binomial regression.
RESULTS: The treated EBRT volumes varied for the different techniques with ~2500 cm3 for 3D conformal radiotherapy (3D-CRT), ~2000 cm3 for EMBRACE‑I VMAT, and ~1800 cm3 for EMBRACE-II VMAT and ART. In general, a worsening of symptoms during the first 5 treatment weeks and recovery afterwards was observed. Dose-volume parameters significantly correlating with stool urgency, rectal and urinary incontinence were as follows: bowel V40Gy < 250 cm3, rectum V40Gy < 80% and bladder V40Gy < 80-90%.
CONCLUSION: This prospective study demonstrated the impact of EBRT treatment techniques in combination with chemotherapy on early morbidity. Dose-volume effects for dysuria, urinary incontinence, stool urgency, diarrhea, rectal bleeding, rectal incontinence and weight loss were found.

Entities:  

Keywords:  Brachytherapy; Image-guided adaptive radiotherapy; Organs-at-risk toxicity; Quality of life; Radiotherapy

Year:  2021        PMID: 33929558     DOI: 10.1007/s00066-021-01781-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  43 in total

1.  Motion and deformation of the target volumes during IMRT for cervical cancer: what margins do we need?

Authors:  Linda van de Bunt; Ina M Jürgenliemk-Schulz; Gérard A P de Kort; Judith M Roesink; Robbert J H A Tersteeg; Uulke A van der Heide
Journal:  Radiother Oncol       Date:  2008-01-30       Impact factor: 6.280

2.  An assessment of interfractional uterine and cervical motion: implications for radiotherapy target volume definition in gynaecological cancer.

Authors:  Alexandra Taylor; Melanie E B Powell
Journal:  Radiother Oncol       Date:  2008-06-05       Impact factor: 6.280

3.  Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study.

Authors:  Nina Boje Kibsgaard Jensen; Richard Pötter; Kathrin Kirchheiner; Lars Fokdal; Jacob Christian Lindegaard; Christian Kirisits; Renaud Mazeron; Umesh Mahantshetty; Ina Maria Jürgenliemk-Schulz; Barbara Segedin; Peter Hoskin; Kari Tanderup
Journal:  Radiother Oncol       Date:  2018-06-04       Impact factor: 6.280

4.  Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study.

Authors:  Kathrin Kirchheiner; Richard Pötter; Kari Tanderup; Jacob C Lindegaard; Christine Haie-Meder; Primož Petrič; Umesh Mahantshetty; Ina M Jürgenliemk-Schulz; Bhavana Rai; Rachel Cooper; Wolfgang Dörr; Remi A Nout
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-12-29       Impact factor: 7.038

5.  Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy.

Authors:  Xue-lian Du; Jiang Tao; Xiu-gui Sheng; Chun-hua Lu; Hao Yu; Cong Wang; Qu-qing Song; Qing-shui Li; Chun-xia Pan
Journal:  Gynecol Oncol       Date:  2011-12-22       Impact factor: 5.482

6.  Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.

Authors:  Ajeet Kumar Gandhi; Daya Nand Sharma; Goura Kisor Rath; Pramod Kumar Julka; Vellaiyan Subramani; Seema Sharma; Durai Manigandan; M A Laviraj; Sunesh Kumar; Sanjay Thulkar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-11-01       Impact factor: 7.038

7.  Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer.

Authors:  Lars Fokdal; Richard Pötter; Kathrin Kirchheiner; Jacob Chr Lindegaard; Nina Boje Kibsgaard Jensen; Christian Kirisits; Cyrus Chargari; Umesh Mahantshetty; Ina Maria Jürgenliemk-Schulz; Barbara Segedin; Peter Hoskin; Kari Tanderup
Journal:  Radiother Oncol       Date:  2018-05-18       Impact factor: 6.280

8.  The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer.

Authors:  David Cibula; Richard Pötter; François Planchamp; Elisabeth Avall-Lundqvist; Daniela Fischerova; Christine Haie Meder; Christhardt Köhler; Fabio Landoni; Sigurd Lax; Jacob Christian Lindegaard; Umesh Mahantshetty; Patrice Mathevet; W Glenn McCluggage; Mary McCormack; Raj Naik; Remi Nout; Sandro Pignata; Jordi Ponce; Denis Querleu; Francesco Raspagliesi; Alexandros Rodolakis; Karl Tamussino; Pauline Wimberger; Maria Rosaria Raspollini
Journal:  Radiother Oncol       Date:  2018-05-01       Impact factor: 6.280

9.  Inter- and intrafractional tumor and organ movement in patients with cervical cancer undergoing radiotherapy: a cinematic-MRI point-of-interest study.

Authors:  Philip Chan; Robert Dinniwell; Masoom A Haider; Young-Bin Cho; David Jaffray; Gina Lockwood; Wilfred Levin; Lee Manchul; Anthony Fyles; Michael Milosevic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

10.  Cervix regression and motion during the course of external beam chemoradiation for cervical cancer.

Authors:  Beth M Beadle; Anuja Jhingran; Mohammad Salehpour; Marianne Sam; Revathy B Iyer; Patricia J Eifel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-29       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.